KMT2A and leukemia: The MLL/AF4 fusion was described to mediate high BCL-2 expression leading to VEN sensitivity34, and response was reported in four out of four samples tested in an ex vivo drug screen and in three out of six MLL/AF4 positive leukemias upon in vivo treatment21,36.